Phaseline

Companies › UniQure Biopharma

UniQure Biopharma: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 5 Phase 1; Neurology, Metabolic and endocrine; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AAV9-hSyn1-miGRIK2 (AMT-260)
AAV9 gene therapy delivering miRNA to silence GRIK2 and suppress GluK2-containing kainate
GRIK2Phase 1Mesial Temporal Lobe EpilepsyNov 2026
AMT-191
AAV5-based gene therapy delivering human α-galactosidase A
GLAPhase 1Fabry DiseaseDec 2027
AMT-130
rAAV5-miHTT gene therapy - delivers microRNA targeting mutant huntingtin (HTT) mRNA
HTTPhase 1Huntington Disease; Huntington's DiseaseMar 2029
AMT-162
Self-complementary AAV serotype rh10 vector delivering miRNA targeting SOD1
SOD1Phase 1Amyotrophic Lateral SclerosisJun 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06063850AAV9-hSyn1-miGRIK2 (AMT-260)Phase 1Mesial Temporal Lobe EpilepsyNeurologyNov 2026
NCT06270316AMT-191Phase 1Fabry DiseaseMetabolic and endocrineDec 2027
NCT05243017AMT-130Phase 1Huntington DiseaseNeurologyMar 2029
NCT04120493AMT-130Phase 1Huntington's DiseaseNeurologyJun 2029
NCT06100276AMT-162Phase 1Amyotrophic Lateral SclerosisNeurologyJun 2031

Targets

GRIK2 (1) GLA (1) HTT (1) SOD1 (1)

Companies with the same targets

Roche Chiesi Farmaceutici Amicus Therapeutics Takeda 4D Molecular Therapeutics Alnylam Pharmaceuticals Novartis ExoRNA Bioscience Biogen Regeneron Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.